| Literature DB >> 22848470 |
Sameena Nawaz1, David J Allen, Farah Aladin, Christopher Gallimore, Miren Iturriza-Gómara.
Abstract
Gastroenteritis is a common illness causing considerable morbidity and mortality worldwide. Despite improvements in detection methods, a significant diagnostic gap still remains. Human bocavirus (HBoV)s, which are associated with respiratory infections, have also frequently been detected in stool samples in cases of gastroenteritis, and a tentative association between HBoVs, and in particular type-2 HBoVs, and gastroenteritis has previously been made. The aim of this study was to determine the role of HBoVs in gastroenteritis, using archived DNA samples from the case-control Infectious Intestinal Disease Study (IID). DNA extracted from stool samples from 2,256 cases and 2,124 controls were tested for the presence of HBoV DNA. All samples were screened in a real time PCR pan-HBoV assay, and positive samples were then tested in genotype 1 to 3-specific assays. HBoV was detected in 7.4% but no significantly different prevalence was observed between cases and controls. In the genotype-specific assays 106 of the 324 HBoV-positive samples were genotyped, with HBoV-1 predominantly found in controls whilst HBoV-2 was more frequently associated with cases of gastroenteritis (p<0.01). A significant proportion of HBoV positives could not be typed using the type specific assays, 67% of the total positives, and this was most likely due to low viral loads being present in the samples. However, the distribution of the untyped HBoV strains was no different between cases and controls. In conclusion, HBoVs, including HBoV-2 do not appear to be a significant cause of gastroenteritis in the UK population.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22848470 PMCID: PMC3404102 DOI: 10.1371/journal.pone.0041346
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
HBoV-specific oligonucleotide primers and probes (all located at the NS gene).
| Primers | Sequence (5′-3′) | Nt positions | reference |
| Pan qpcr primers | |||
| Pan-HBoV-F |
| 1994–2020 | Ratcliff et al |
| Pan-HBoV-R | AGT GCA GWA | 2079-2059 | Ratcliff et al |
| Pan HBoV1-F | TCT CC | 201–219 | This study |
| Type-specific qpcr primers (anti-sense) | |||
| HBoV1-R |
| 424-407 | This study |
| HBoV2-R |
| 427-410 | This study |
| HBoV3-R | CAT | 405-392 | This study |
| Generic PCR primers for sequencing | |||
| HBoV01.2F |
| 2091 |
|
| HBoV02.2R |
| 1791 |
|
| Probes | |||
| pan HBoV-NS1 | 6FAM-CCT TTG TCC TAC WCA TTC-MGBBNFQ | 2025–2042 | Ratcliff et al |
| HBoV-1 | 6Fam- TAT CAT AGA TTG TTC AGT TCC AGT AGC-MGBBNFQ | 393-372 | This study |
| HBoV-2 | 6Vic- TT GGA TCA TGA GAC GTT CAG TCC C-MGBBNFQ | 399-376 | This study |
| HBoV-3 | 6Ned- CTG GAT CAT GGC TTG CTC GGT A-MGBBNFQ | 377-351 | This study |
Unpublished method, personal communication.
Age distribution of HBoV positive samples in cases and controls of IID.
| CASES | CONTROLS | ALLTOTAL | ||||||||
| Age Group (years) | HBoV pos | % | TOTAL | HBoV pos | % | TOTAL | POR | HBoV pos | % | TOTAL |
| <1 | 34 | 26.2 | 130 | 62 | 34.8 | 178 | 0.66514 | 96 | 31.2 | 308 |
| 1–4 | 58 | 12.2 | 476 | 91 | 18.0 | 506 | 0.633 | 149 | 15.2 | 982 |
| 5–9 | 9 | 6.9 | 131 | 8 | 6.0 | 134 | 1.16112 | 17 | 6.4 | 265 |
| 10–19 | 5 | 4.4 | 114 | 2 | 1.9 | 103 | 2.37635 | 7 | 3.2 | 217 |
| 20–29 | 7 | 2.4 | 286 | 2 | 1.1 | 177 | 2.21088 | 9 | 1.9 | 463 |
| 30–39 | 8 | 2.2 | 365 | 3 | 1.0 | 294 | 2.22699 | 11 | 1.7 | 659 |
| 40–49 | 11 | 4.4 | 249 | 2 | 0.8 | 240 | 5.70711 | 13 | 2.7 | 489 |
| 50–59 | 8 | 4.0 | 199 | 1 | 0.5 | 192 | 8.29167 | 9 | 2.3 | 391 |
| 60–69 | 5 | 2.9 | 175 | 3 | 1.7 | 177 | 1.72696 | 8 | 2.3 | 352 |
| >70 | 4 | 3.1 | 131 | 1 | 0.8 | 123 | 3.96698 | 5 | 2.0 | 254 |
|
|
|
|
|
|
|
|
|
|
|
|
POR = prevalence odds ratio.
Figure 1HBoV detection assays, CT distribution in cases and controls.
Distribution of HBoV-positive samples in cases and controls with or without a co-infection.
| CASES | CONTROLS | TOTAL | ||||
| Age Group | Single HBoV | Multiple infections | Single HBoV | Multiple infections | Single HBoV | All HBoV positives |
| <1 | 18 | 16 | 24 | 38 | 42 | 96 |
| 1–4 | 17 | 41 | 51 | 40 | 68 | 149 |
| 5–9 | 2 | 7 | 4 | 4 | 6 | 17 |
| 10–19 | 0 | 5 | 1 | 1 | 1 | 7 |
| 20–29 | 4 | 3 | 2 | 0 | 6 | 9 |
| 30–39 | 4 | 4 | 2 | 1 | 6 | 11 |
| 40–49 | 6 | 5 | 2 | 0 | 8 | 13 |
| 50–59 | 5 | 3 | 1 | 0 | 6 | 9 |
| 60–69 | 3 | 2 | 1 | 2 | 4 | 8 |
| >70 | 2 | 2 | 0 | 1 | 2 | 5 |
| TOTAL | 61 | 88 | 88 | 87 | 149 | 324 |
|
|
|
|
|
|
| |
Figure 2Temporal distribution of HBoV infections.
Distribution of HBoV genotypes in cases and controls.
| COHORT | Age Group(years) | HBoV-1 | HBoV-1+HBoV-2 | HBoV-2 | HBoV-3 | Untyped | TOTAL |
| CASES | <1 | 1 | 1 | 9 | 2 | 21 | 34 |
| 1–4 | 3 | 1 | 8 | 6 | 40 | 58 | |
| 5–9 | 1 | 1 | 7 | 9 | |||
| 10–19 | 2 | 1 | 2 | 5 | |||
| 20–29 | 2 | 5 | 7 | ||||
| 30–39 | 3 | 5 | 8 | ||||
| 40–49 | 2 | 9 | 11 | ||||
| 50–59 | 3 | 5 | 8 | ||||
| >70 | 2 | 2 | 4 | ||||
| 60–69 | 5 | 5 | |||||
| CASES Total | 4 | 2 | 32 | 10 | 101 | 149 | |
|
|
|
|
|
|
|
| |
| CONTROLS | <1 | 10 | 1 | 10 | 4 | 37 | 62 |
| 1–4 | 14 | 8 | 6 | 63 | 91 | ||
| 5–9 | 1 | 7 | 8 | ||||
| 10–19 | 2 | 2 | |||||
| 20–29 | 2 | 2 | |||||
| 30–39 | 2 | 1 | 3 | ||||
| 40–49 | 2 | 2 | |||||
| 50–59 | 1 | 1 | |||||
| 60–69 | 1 | 2 | 3 | ||||
| >70 | 1 | 1 | |||||
| CONTROLS Total | 24 | 1 | 19 | 14 | 117 | 175 | |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
Summary of published studies on the prevalence of HBoV in stool samples.
| Country | Sampling date | Cases No | Controls No | Population studied | % CasesHBoV-pos | % Controls HBoV-pos | Main Conclusion | Ref |
| Australia | Jan-Dec 2001. | 186 | 186 | Paediatric | 17.20% | 8.10% | HBoV-2 associated with gastroenteritis (only if cases with a concomitant bacterial infection included). |
|
| (HBoV-2) | (HBoV-2) | Temporal pattern observed : summer months. | ||||||
| Brazil | Jan 2003–Dec 2005. | 705 | ND | Paediatric | 2.0% (HBoV) | ND | No obvious temporal clustering of the HBoV-positive patients. | [39] |
| China | July 2006–Sept 2007. | 397 | 115 | Paediatric | 3.50% (HBoV) | 3.50% (HBoV) | HBoV not associated with gastroenteritis. Temporal patterns observed : winter months. |
|
| China | July 2006–June 2008. | 632 | 162 | Paediatric | 20.40% (HBoV-2) | 12.30% (HBoV-2) | No statistically significant association between HBoV detection and gastroenteritis. |
|
| Germany | Jan-Feb and Sept–Dec 2007. | 307 | ND | Paediatric (daycare outbreaks) | 4.60% (HBoV) | HBoV was not associated with outbreaks of gastroenteritis in childrenin day care. | [40] | |
| Hong Kong | Nov 2004–Oct 2005. | 1,435 | ND | ND | 2.10% | Same virus found in respiratory and stool samples. |
| |
| Korea | Jan 2005–Dec 2006. | 962 | ND | Paediatric | 0.80% (HBoV) | Temporal patterns observed : summer months. | [41] | |
| South Korea | May 2008–April 2009. | 358 | ND | Paediatric | 0.5% (HBoV-1) 3.6% (HBoV-2) | Temporal pattern observed : winter months. |
| |
| Spain | Dec 2005–Mar 2006. | 527 | ND | Paediatric | 9.10% (HBoV) | Prevalence of HBoVs in respiratory and stool samples was similar. | [42] | |
| Thailand | Nov 2005–Sep 2006. | 225 | 202 | Paediatric | 0.90% (HBoV) | 0 | Low prevalence. No statistically significant difference between casesand controls (p = 0.17). | [43] |
| USA | Dec 1–Marc 31 2008. | 479 | ND | Paedriatic and adult | 1.30% (HBoV2) | 0.7% children and 1.5% adults. | [45] |